The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Category: University College London Hospitals NHS Foundation Trust
The most common form of cancer in men is responsible for 12,000 deaths every year in the UK
The trial is recruiting patients in Leeds, Manchester, Oxford, London, Cambridge and Kent